BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gilson C, Chowdhury S, Parmar MKB, Sydes MR; STAMPEDE Investigators. Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clin Oncol (R Coll Radiol) 2017;29:778-86. [PMID: 29079227 DOI: 10.1016/j.clon.2017.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Langley RE. The direction of travel to better outcomes for patients with oesophago-gastric cancer. J Thorac Dis 2018;10:1236-8. [PMID: 29708129 DOI: 10.21037/jtd.2018.03.23] [Reference Citation Analysis]
2 Meyer EL, Mesenbrink P, Dunger-baldauf C, Fülle H, Glimm E, Li Y, Posch M, König F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics 2020;42:1330-60. [DOI: 10.1016/j.clinthera.2020.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
3 Parry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, Ubertini V, Ramani V, Lau M, Shanks J, Nonaka D, Oliveira P, Hambrock T, Leong HS, Dhomen N, Miller C, Brady G, Dive C, Clarke NW, Marais R, Baena E. Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. Eur Urol Oncol 2019;2:1-11. [PMID: 30929837 DOI: 10.1016/j.euo.2018.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
4 Ajithkumar TV, Gilbert DC. Modern Challenges of Cancer Clinical Trials. Clin Oncol (R Coll Radiol) 2017;29:767-9. [PMID: 29066171 DOI: 10.1016/j.clon.2017.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
5 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials 2020;21:528. [PMID: 32546273 DOI: 10.1186/s13063-020-04334-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, Lester RT, Thorlund K, Mills EJ. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 2019;20:572. [PMID: 31533793 DOI: 10.1186/s13063-019-3664-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 21.0] [Reference Citation Analysis]
7 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 2020;369:m115. [PMID: 32554564 DOI: 10.1136/bmj.m115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
8 Siden EG, Park JJ, Zoratti MJ, Dron L, Harari O, Thorlund K, Mills EJ. Reporting of master protocols towards a standardized approach: A systematic review. Contemp Clin Trials Commun 2019;15:100406. [PMID: 31334382 DOI: 10.1016/j.conctc.2019.100406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
9 Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard AC, Delva R, Rolland F, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero JM, Ravaud A, Krakowski I, Lagrange JL, Deplanque G, Zylberait D, Bozec L, Houede N, Culine S, Elaidi R. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. JAMA Oncol 2019;5:623-32. [PMID: 30703190 DOI: 10.1001/jamaoncol.2018.6607] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
10 Aragon-Ching JB, Dreicer R. Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. Expert Rev Anticancer Ther 2020;20:483-90. [PMID: 32406281 DOI: 10.1080/14737140.2020.1770087] [Reference Citation Analysis]